CureVac’s stock soars on GSK’s $1.56 billion deal for its COVID-19 and flu vaccines

U.K. pharmaceutical giant GSK said the deal gives it the rights to develop, manufacture and commercialize messenger RNA-based candidate vaccines for flu and COVID-19.